Hematopoietic stimulation

Abstract

Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.

1 . A method for treating a subject to stimulate hematopoiesis in the subject, comprising: 
 administering to a subject in need of such treatment an amount of an agent effective to increase the number of hematopoietic cells or mature blood cells in the subject, wherein the amount is less than 1 mg/kg body weight per day and wherein the agent is a compound of Formula I.    
   
   
       2 . The method of  claim 1 , wherein the subject has an abnormally low level of hematopoietic cells and wherein the agent is administered in an amount effective to restore levels of a hematopoietic cell-type to a preselected normal or protective level.  
   
   
       3 . The method of  claim 1 , wherein the subject is administered at least two doses of the agent in an 18 hour period.  
   
   
       4 . The method of  claim 2 , wherein the subject is neutropenic and wherein said amount is effective to restore a preselected normal or protective level of neutrophils.  
   
   
       5 . The method of  claim 2 , wherein the subject has abnormally low levels of erythrocytes and wherein said amount is effective to restore a preselected normal or protective level of erythrocytes.  
   
   
       6 . The method of  claim 2 , wherein the subject has abnormally low levels of platelets and wherein said amount is effective to restore a preselected normal or protective level of platelets.  
   
   
       7 . The method of  claim 1 , wherein the agent is ValBoroPro.  
   
   
       8 . A method for shortening the time that a subject has an abnormally low level of hematopoietic or mature blood cells resulting from treatment with a hematopoietic cell inhibitor, comprising: 
 administering to a subject in need of such treatment an agent in an amount effective to increase the number of hematopoietic cells or mature blood cells in the subject,    wherein the administration of the agent is prior to or substantially simultaneous with administration of the hematopoietic cell inhibitor, and wherein the agent is a compound of Formula I.    
   
   
       9 . The method of  claim 8 , wherein the administration of the hematopoietic cell inhibitor  
     causes an abnormally low level of hematopoietic cells in the subject and wherein the agent is administered in an amount effective to restore levels of a hematopoietic cell-type to a preselected normal or protective level.  
   
   
       10 . The method of  claim 9 , wherein the subject is administered at least two doses of the agent in an 18 hour period.  
   
   
       11 . The method of  claim 9 , wherein the hematopoietic cell inhibitor reduces in the subject neutrophils and wherein the amount is effective to restore in the subject a preselected normal or protective level of neutrophils.  
   
   
       12 . The method of  claim 9 , wherein the hematopoietic cell inhibitor reduces in the subject erythrocytes and wherein the amount is effective to restore in the subject a preselected normal or protective level of erythrocytes.  
   
   
       13 . The method of  claim 9 , wherein the hematopoietic cell inhibitor reduces in the subject platelets and wherein the amount is effective to restore in the subject a preselected normal or protective level of platelets.  
   
   
       14 . The method of  claim 8 , wherein the amount is less than 1 mg/kg body weight per day.  
   
   
       15 . The method of  claim 8 , wherein the agent is ValBoroPro.  
   
   
       16 . A method for preparing a subject for treatment with a hematopoietic cell inhibitor, comprising: 
 administering to the subject prior to the subject receiving the hematopoietic cell inhibitor an agent in an amount effective to stimulate in the subject production of growth factor, wherein the agent is a compound of Formula I.    
   
   
       17 . The method of  claim 16 , wherein the growth factor is granulocyte colony stimulating factor.  
   
   
       18 . The method of  claim 16 , wherein the amount is less than 1 mg/kg body weight per day.  
   
   
       19 . The method of  claim 16 , wherein the agent is administered to the subject by administering at least two doses of the agent in an 18 hour period.  
   
   
       20 . The method of  claim 16 , wherein the agent stimulates stromal cell production of growth factor.  
   
   
       21 .- 63 . (canceled)